Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The pharmaceuticals business recorded higher revenue due to solid sales of the Aisuirui pharmaceutical product and strengthened sales and marketing activities. The medical devices business recorded lower revenue due to the impact of revisions to the U.S. Medicare system, despite the consolidation effect of ZOO LABO. On the earnings side, the ¥6,596 million gain from the reversal of accrued interest payable contributed to higher profit, while expenses related to acquisitions and integration, F351, and share-based compensation were incurred.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥11,937 million (YoY -2.6%) |
| Operating profit | ¥534 million |
| Ordinary income | ¥-87 million |
| Profit attributable to owners of the parent | ¥-1,988 million |
| Net income per share | △¥35.66 |
| Equity ratio | End of the current fiscal period 49.5 / End of previous period 60.1 |
| Total assets | ¥81,760 million |
| Net assets | ¥66,497 million |
| Cash flows from operating activities | ¥-1,606 million |
| Cash flows from investing activities | ¥-2,505 million |
| Cash flows from financing activities | ¥-191 million |
| Cash and cash equivalents at end of period | ¥17,164 million |
| Full-year earnings forecast | Net Sales ¥47,327 million (YoY +76.3%) / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥47,327 million / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Pharmaceuticals Business ¥8,919 million (YoY +8.8%), Medical Equipment Business ¥3,017 million (YoY -25.6%) |
| Segment profit | Pharmaceuticals Business ¥2,734 million, Medical Equipment Business ¥-2,200 million |
| Depreciation and amortization | ¥630 million |
| Breakdown of extraordinary income (loss) | Gain on reversal of accrued interest payable (other income) 6,596 |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | The acquisition of all shares of あゆみ製薬ホールディングス株式会社, making it a wholly owned subsidiary effective 1 July 2026; a third-party allotment of shares relating to part of the acquisition consideration; and a ¥20,000 million borrowing to fund the acquisition. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 55,843,127 |
| Treasury Shares at Period-End | 13,643 |
| Factors Behind Changes in Business Performance | The pharmaceuticals business recorded higher revenue due to solid sales of the Aisuirui pharmaceutical product and strengthened sales and marketing activities. The medical devices business recorded lower revenue due to the impact of revisions to the U.S. Medicare system, despite the consolidation effect of ZOO LABO. On the earnings side, the ¥6,596 million gain from the reversal of accrued interest payable contributed to higher profit, while expenses related to acquisitions and integration, F351, and share-based compensation were incurred. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmaceuticals business, sales of the Aisuirui pharmaceutical product remained solid, and the effects of strengthened sales and marketing activities also emerged. In the medical devices business, revenue declined due to the impact of revisions to the U.S. Medicare system. On the earnings side, a gain of ¥6,596 million from the reversal of accrued interest payable contributed to higher profit, but expenses related to acquisitions and integration, commercialization preparation for F351, research and development, and share-based compensation were incurred. The reason for not disclosing profit forecasts is that the timing and scale of upfront investment toward new drug approvals and development remain fluid, making a reasonable estimate difficult at this time.